Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
26 Julho 2023 - 7:58PM
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, today launched
Valence Labs at the International Conference on Machine Learning
(ICML). Valence Labs will serve as a machine learning research
laboratory focused on developing the next generation of
cutting-edge methods and models for drug discovery and consists of
the emerging ML research teams at Recursion and the team at Valence
Discovery, which Recursion recently acquired.
“We believe there is a generational opportunity—enabled by the
unprecedented combination of Recursion’s scale, computing power,
and industrialized data generation capabilities unconstrained by
one-off, rate-limiting, manual experimentation—to rewrite the rules
of therapeutic discovery,” said Dan Cohen, President of Valence
Labs. “We’re building future-forward tools, models and benchmarks
that we believe will set the standard for machine learning research
across the rapidly growing techbio industry, while fostering
community through open science and academic research.”
At its launch event, Valence Labs committed to investing up to
$1 million in academic-oriented initiatives to develop talent in
machine learning research. This will include Valence Scholarships
to support the pursuit of more academic research at the
intersection of artificial intelligence and biology, and Valence
Fellows for outstanding students with a track record of community
engagement and/or publication in the field of machine learning for
drug discovery, who will receive larger financial support and
access to Valence Labs resources to enable their research.
"Recursion believes in the power of open-science initiatives and
wants to invest in rising talent and academic collaborations. We
are also committed to upholding our legacy of contributing
significant datasets and tools for research purposes," said Chris
Gibson, Ph.D., Co-founder and CEO of Recursion. "We believe Valence
Labs can serve as a beacon and gathering place for the research
community, becoming a magnet for incredible talent who will
contribute to groundbreaking discoveries and harness computation to
radically improve lives."
About Valence LabsValence Labs, formerly
Valence Discovery, is a company harnessing computation to radically
improve lives. With roots at Mila and mentorship from Yoshua
Bengio, the company is dedicated to advancing deep learning in drug
discovery, delivering impactful research and transformative
technology, and embracing open-source and open-science knowledge
sharing with the machine learning community.
Having bested industry giants in machine learning competitions
and after gaining a deeper understanding of drug discovery
intricacies, they teamed up with Recursion to combine Valence’s
models with Recursion’s fit-for-purpose datasets to make better
predictions and choose better experiments with a lower failure
rate, at greater speed, and at a lesser cost. Combining the
intellectual freedom of academia with the resources and stability
of industry, Valence Labs takes a long-term view on technology
development: acting boldly, leaning into risks, embracing failure,
and ultimately trading incremental improvements for the
breakthrough advances they hope will redefine the field. Learn more
at www.ValenceLabs.com, or connect on Twitter and LinkedIn.
About RecursionRecursion (NASDAQ: RXRX) is a
clinical stage TechBio company leading the space by decoding
biology to industrialize drug discovery. Enabling its mission is
the Recursion OS, a platform built across diverse technologies that
continuously expands one of the world’s largest proprietary
biological and chemical datasets. Recursion leverages sophisticated
machine-learning algorithms to distill from its dataset a
collection of trillions of searchable relationships across biology
and chemistry unconstrained by human bias. By commanding massive
experimental scale — up to millions of wet lab experiments weekly —
and massive computational scale — owning and operating one of the
most powerful supercomputers in the world, Recursion is uniting
technology, biology, and chemistry to advance the future of
medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montréal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on Twitter and LinkedIn.
Forward-Looking StatementsThis document
contains information that includes or is based upon
"forward-looking statements" within the meaning of the Securities
Litigation Reform Act of 1995, including, without limitation, those
regarding early and late stage discovery, preclinical, and clinical
programs; licenses and collaborations; prospective products and
their potential future indications and market opportunities; the
Recursion OS and other technologies; business and financial plans
and performance; and all other statements that are not historical
facts. Forward-looking statements may or may not include
identifying words such as "plan," "will," "expect," "anticipate,"
"intend," "believe," "potential," "continue," and similar terms.
These statements are subject to known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements, including but
not limited to: challenges inherent in pharmaceutical research and
development, including the timing and results of preclinical and
clinical programs, where the risk of failure is high and failure
can occur at any stage prior to or after regulatory approval due to
lack of sufficient efficacy, safety considerations, or other
factors; our ability to leverage and enhance our drug discovery
platform; our ability to obtain financing for development
activities and other corporate purposes; the success of our
collaboration activities; our ability to obtain regulatory approval
of, and ultimately commercialize, drug candidates; our ability to
obtain, maintain, and enforce intellectual property protections;
cyberattacks or other disruptions to our technology systems; our
ability to attract, motivate, and retain key employees and manage
our growth; and other risks and uncertainties such as those
described under the heading "Risk Factors" in our filings with the
U.S. Securities and Exchange Commission, including our most recent
Quarterly Report on Form 10-Q and our Annual Report on Form 10-K.
All forward-looking statements are based on management's current
estimates, projections, and assumptions, and Recursion undertakes
no obligation to correct or update any such statements, whether as
a result of new information, future developments, or otherwise,
except to the extent required by applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024